|
|
 | | | |
- close
- close
- close
- close
Medicis Pharmaceutical (MRX) |
QUOTE AND NEWS
Benzinga
Apr 18
Comment
JP Morgan increases its price target from $42 to $45 on Overweight-rated Medicis Pharmaceutical (NYSE: MRX) to reflect encouraging feedback on Zyclara.
JP Morgan comments, "We continue to see MRX shares extremely well positioned as the...
Market Intelligence Center
Apr 10
Comment
Medicis Pharmaceutical (NYSE:MRX) closed Monday's unfavorable trading session at $38.45. In the past year, the stock has hit a 52-week low of $29.76 and 52-week high of $40.51. Medicis Pharmaceutical (MRX) stock has been showing support around...
Globe Newswire
Apr 4
Comment
SCOTTSDALE, Ariz., April 4, 2012 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that proxy materials are available via the Internet for its 2012 Annual Meeting of Stockholders under the U.S. Securities and Exchange Commission's (SEC) notice
Market Intelligence Center
Apr 2
Comment
Medicis Pharmaceutical Corp (NYSE: MRX) closed Friday's trading session at $37.59. In the past year, the stock has hit a 52-week low of $29.76 and 52-week high of $40.51. Medicis Pharmaceutical (MRX) stock has been showing support around $37.20...
Benzinga
Mar 29
Comment
Below are the top mid-cap drugs-generic stocks on the NYSE and the NASDAQ in terms of earnings per share.
The trailing-twelve-month earnings per share at Watson Pharmaceuticals Inc (NYSE: WPI) is $2.06. WPI's ROE for the same period is...
PR Newswire
Mar 27
Comment
CHICAGO, March 27, 2012 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for AMZN, GG, AEO, TPX, and MRX. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch
Benzinga
Mar 23
Comment
Hyperion Therapeutics, Inc. today announced that it has acquired worldwide rights to the investigational drug Ravicti™ (glycerol phenylbutyrate) from Ucyclyd Pharma, Inc., a wholly owned subsidiary of Medicis Pharmaceutical Corporation (NYSE:...
Globe Newswire
Mar 16
Comment
SCOTTSDALE, Ariz., March 16, 2012 (GLOBE NEWSWIRE) -- Named to World's Most Ethical Companies List for Second, Consecutive Year Company Credits Its Compliance Leadership & Philanthropic Engagement Medicis (NYSE:MRX) today announced it has been
Market Intelligence Center
Mar 14
Comment
Medicis Pharmaceutical Corp (NYSE: MRX) closed Tuesday's trading session at $37.11. In the past year, the stock has hit a 52-week low of $29.33 and 52-week high of $40.51. Medicis Pharmaceutical (MRX) stock has been showing support around $36.27...
Benzinga
Mar 9
Comment
Goldman Sachs raises its rating on Medicis Pharmaceutical (NYSE: MRX) to Buy and raises its price target to $43 as the company leverages its key strengths.
Goldman Sachs says, "We believe that after years of playing defense against exclusivity...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
